PRINCIPAL FINANCIAL GROUP INC - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 335 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 1.07 and the average weighting 0.2%.

Quarter-by-quarter ownership
PRINCIPAL FINANCIAL GROUP INC ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$22,562,868
+17.5%
590,651
+10.9%
0.02%
+23.1%
Q2 2023$19,208,284
-9.5%
532,528
-4.2%
0.01%
-13.3%
Q1 2023$21,226,918
-45.2%
555,824
-18.4%
0.02%
-48.3%
Q4 2022$38,762,216
+81.0%
681,234
+25.8%
0.03%
+70.6%
Q3 2022$21,414,000
-23.3%
541,579
-14.7%
0.02%
-19.0%
Q2 2022$27,920,000
+42.8%
634,560
+29.4%
0.02%
+75.0%
Q1 2022$19,550,000
-1.3%
490,218
-0.5%
0.01%0.0%
Q4 2021$19,805,000
-9.5%
492,521
-8.4%
0.01%
-14.3%
Q3 2021$21,878,000
-5.3%
537,812
+5.7%
0.01%
-6.7%
Q2 2021$23,111,000
+13.6%
508,947
+4.3%
0.02%
+7.1%
Q1 2021$20,338,000
+10.5%
487,823
+13.2%
0.01%0.0%
Q4 2020$18,398,000
+1257.8%
430,752
+735.9%
0.01%
+1300.0%
Q3 2020$1,355,000
-6.7%
51,534
-4.9%
0.00%0.0%
Q2 2020$1,452,000
+103.6%
54,162
+36.6%
0.00%0.0%
Q1 2020$713,000
+1.1%
39,641
-0.3%
0.00%0.0%
Q4 2019$705,000
+2.5%
39,767
-10.3%
0.00%0.0%
Q3 2019$688,000
-0.4%
44,344
+10.3%
0.00%0.0%
Q2 2019$691,000
-51.9%
40,195
-55.0%
0.00%0.0%
Q1 2019$1,437,000
+12.3%
89,288
+2.0%
0.00%0.0%
Q4 2018$1,280,000
-19.3%
87,537
+0.2%
0.00%0.0%
Q3 2018$1,587,000
+16.9%
87,321
+8.6%
0.00%0.0%
Q2 2018$1,357,000
+65.1%
80,430
+91.7%
0.00%0.0%
Q1 2018$822,000
-3.0%
41,951
+0.4%
0.00%0.0%
Q4 2017$847,000
+188.1%
41,785
+146.7%
0.00%
Q3 2017$294,000
+14.8%
16,941
-15.2%
0.00%
Q2 2017$256,000
-4.1%
19,982
-3.0%
0.00%
Q1 2017$267,000
+34.8%
20,602
+2.8%
0.00%
Q4 2016$198,000
-15.4%
20,044
+3.3%
0.00%
Q3 2016$234,000
+41.0%
19,404
+1.1%
0.00%
Q2 2016$166,000
-6.2%
19,188
+2.6%
0.00%
Q1 2016$177,000
-44.2%
18,696
+2.1%
0.00%
Q4 2015$317,000
+31.5%
18,315
+2.1%
0.00%
Q3 2015$241,000
-41.6%
17,945
-1.9%
0.00%
-100.0%
Q2 2015$413,000
+70.7%
18,286
+7.6%
0.00%
Q1 2015$242,000
+45.8%
16,990
-1.2%
0.00%
Q4 2014$166,000
-10.8%
17,202
-15.7%
0.00%
Q3 2014$186,000
-7.0%
20,398
+0.7%
0.00%
Q2 2014$200,000
-43.8%
20,262
-27.7%
0.00%
-100.0%
Q1 2014$356,000
-3.5%
28,028
+13.8%
0.00%0.0%
Q4 2013$369,000
+35.7%
24,6210.0%0.00%0.0%
Q3 2013$272,000
+23.6%
24,621
-11.2%
0.00%
Q2 2013$220,00027,7190.00%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q1 2021
NameSharesValueWeighting ↓
Third Security, LLC 1,129,551$47,091,0006.38%
First Light Asset Management, LLC 2,011,350$83,853,0005.56%
TRAN CAPITAL MANAGEMENT, L.P. 1,353,208$56,415,0005.03%
SNYDER CAPITAL MANAGEMENT L P 2,920,860$121,771,0003.50%
DOHENY ASSET MANAGEMENT /CA 120,028$5,004,0003.39%
SILVERARC CAPITAL MANAGEMENT, LLC 104,945$4,375,0002.39%
Redwood Investments, LLC 542,764$22,628,0001.99%
Kent Lake Capital LLC 85,000$3,544,0001.44%
Lisanti Capital Growth, LLC 263,460$10,984,0001.41%
Bellevue Group AG 3,011,966$125,569,0001.33%
View complete list of HALOZYME THERAPEUTICS INC shareholders